X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CBX-12 is a PDC that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 demonstrated safety and tolerability, without significant gastrointestinal toxicity.
Lead Product(s): CBX-12
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
Study evaluating the efficacy of CBX-12 (alphalex™-exatecan) in combination with PD-1- and CTLA4-targeted immune checkpoint inhibitors in preclinical cancer models. CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2021
Details:
CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2021
Details:
CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
Proceeds from the financing will be used to support the planned advancement of Cybrexa’s lead candidate CBX-12 (alphalex™-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: HighCape Capital
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 10, 2021
Details:
Cybrexa and NCI to collaborate on clinical development of Cybrexa’s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 24, 2021
Details:
In the GLP toxicology studies CBX-12 was delivered via IV infusion, and based on multiple parameters, including mortality, clinical observations, body weights and food consumption, the results established a significant therapeutic index of ~20X over exatecan for CBX-12.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2021
Details:
The Phase I portion of the study will establish the safety profile and a recommended Phase II dose (RP2D). This initial clinical trial will also evaluate efficacy across a number of solid tumors and establish proof of mechanism for the alphalex™ platform.
Lead Product(s): Alphalex-exatecan
Therapeutic Area: Oncology Product Name: CBX-12
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
CBX-12 demonstrated remarkable efficacy across HER2-negative solid tumors in preclinical models. It displayed enhanced stability in plasma in vivo and demonstrated exquisite selectivity for tumor over normal tissues in mouse tumor models.
Lead Product(s): Alphale-Exatecan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Dr. DeCillis will lead the development of the first-in-human study of Cybrexa’s lead program, CBX-12 (alphalexTM-exatecan), and early and late stage clinical programs for the Cybrexa portfolio.
Lead Product(s): Exatecan
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
